A Phase 2 interventional study of ChimeriVax-WN02 vaccine and ChimeriVax-WN02 vaccine in West Nile Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 15 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-03.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Currently, the only method of prevention of West Nile infection is control of the mosquito vectors associated or avoidance of mosquito bites, which has proven largely ineffective. Developing a safe, effective vaccine and making it widely available will enhance the prospects of prevention and control of this disease. In addition, natural infections with the YF virus and WN virus are more severe in the elderly. Therefore, a study among healthy older subjects or those with well controlled chronic diseases will provide data to determine a ChimeriVax-WN02 vaccine dose that is immunogenic and well tolerated.
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
positive surface antigen (HBsAg), positive (anti-HCV), or positive (HIV).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive ChimeriVax WN02 vaccine, low dose
Biological: ChimeriVax-WN02 vaccine
Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
Biological: ChimeriVax-WN02 vaccine
Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
Biological: ChimeriVax-WN02 vaccine
Participants randomized to receive Placebo (Saline)
Biological: Placebo
low dose, approximately 4 x 3log10, given one time subcutaneously
medium dose, approximately 4 x 4log10, given one time
high dose, approximately 4 x 5log10, given one time subcutaneously
0.9%Normal Saline for Injection, given one time subcutaneously
Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine
Antibodies to the vaccine antigens were measured by the Plaque Reduction Neutralization Test.
Time frame: Day 0 and Day 28 post-vaccination
Number of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
Antibodies to vaccine were measured by the Plaque Reduction Neutralization Test. Seroconversion was defined as a four-fold or greater rise in titer between pre- and post-injection samples; or a post-vaccination (Day 28) titers of ≥ 1:20 in participants with baseline titer ≤ 1:10.
Time frame: Day 0 and Day 28 post-vaccination
Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
Time frame: Day 0 up to Day 14 post-vaccination
Number of Participants Developing Viremia After Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
Viremia is defined as number of subjects in the analysis population dose group with detected (≥ 20 Plaque forming units \[pfu\]/mL) viremia at the reported visit.
Time frame: Day 2 up to Day 14 post-vaccination
Participants were enrolled from 03 October 2008 to 08 December 2008 in 15 clinical centers in the US.
| Milestone | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| Started | 122 | 124 | 113 | 120 |
| Completed | 121 | 122 | 110 | 120 |
| Not completed | 1 | 2 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 0 |
| Withdrew: Participant unable to return for visit | 1 | 0 | 0 | 0 |
Antibodies to the vaccine antigens were measured by the Plaque Reduction Neutralization Test.
| Titers | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| Day 0 | 5.00 (5.00 to 5.00) | 5.76 (4.92 to 6.74) | 5.06 (4.94 to 5.20) | 5.22 (4.80 to 5.68) |
| Day 28 | 688 (453 to 1047) | 600 (405 to 890) | 674 (464 to 978) | 5.93 (4.96 to 7.08) |
Viremia is defined as number of subjects in the analysis population dose group with detected (≥ 20 Plaque forming units \[pfu\]/mL) viremia at the reported visit.
| Participants | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| Day 2 | 1 | 0 | 1 | 0 |
| Day 4 | 33 | 28 | 15 | 0 |
| Day 6 | 21 | 33 | 29 | 0 |
| Day 8 | 19 | 19 | 21 | 0 |
| Day 10 | 15 | 18 | 8 | 1 |
| Day 12 | 7 | 5 | 7 | 0 |
| Day 14 | 2 | 0 | 2 | 0 |
Antibodies to vaccine were measured by the Plaque Reduction Neutralization Test. Seroconversion was defined as a four-fold or greater rise in titer between pre- and post-injection samples; or a post-vaccination (Day 28) titers of ≥ 1:20 in participants with baseline titer ≤ 1:10.
| Participants | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| Number of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine. | 105 | 110 | 103 | 3 |
| Participants | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| Any Pain [N = 122, 123, 112, 120] | 14 | 29 | 10 | 12 |
| Grade 3 Pain (Prevents daily activities) | 0 | 1 | 0 | 0 |
| Any Erythema [N = 122, 123, 112, 120] | 2 | 4 | 0 | 0 |
| Grade 3 Erythema (> 10 cm) | 0 | 0 | 0 | 0 |
| Any Swelling [N = 121, 123, 112, 120] | 1 | 0 | 0 | 0 |
| Grade 3 Swelling (> 10 cm) | 0 | 0 | 0 | 0 |
| Any Fever [N = 122, 123, 111, 120] | 0 | 0 | 3 | 0 |
| Grade 3 Fever (≥ 39.0 ºC or ≥ 102.1 ºF) | 0 | 0 | 1 | 0 |
| Any Headache [N = 122, 123, 112, 120] | 31 | 34 | 33 | 31 |
| Grade 3 Headache (prevents daily activities) | 2 | 3 | 3 | 1 |
| Any Malaise [N = 122, 123, 112, 120] | 26 | 26 | 27 | 25 |
| Grade 3 Malaise (Prevents daily activities) | 2 | 4 | 3 | 2 |
| Any Myalgia [N = 122, 123, 112, 120] | 28 | 25 | 22 | 20 |
| Grade 3 Myalgia (Prevents daily activities) | 2 | 2 | 1 | 0 |
Collected over Adverse events data were collected from the day of vaccination (Day 0) to up to 6 months post-vaccination.. Non-serious events are listed at a 5.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ChimeriVax WN02 Vaccine Low Dose | — | 4/122 (3.3%) | 51/122 (41.8%) |
| ChimeriVax WN02 Vaccine Medium Dose | — | 1/124 (0.8%) | 56/124 (45.2%) |
| ChimeriVax WN02 Vaccine High Dose | — | 3/112 (2.7%) | 42/112 (37.5%) |
| Placebo | — | 5/120 (4.2%) | 54/120 (45%) |
| Event | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/122 | 0/124 | 0/112 | 2/120 |
| Atrial fibrillationCardiac disorders | 1/122 | 0/124 | 1/112 | 0/120 |
| Accidential poisoningInjury, poisoning and procedural complications | 0/122 | 0/124 | 1/112 | 0/120 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/122 | 0/124 | 1/112 | 0/120 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/122 | 0/124 | 1/112 | 0/120 |
| Angina pectorisCardiac disorders | 0/122 | 0/124 | 0/112 | 1/120 |
| Myocardial infarctionCardiac disorders | 0/122 | 0/124 | 0/112 | 1/120 |
| Vitello intestinal duct remnantCongenital, familial and genetic disorders | 0/122 | 0/124 | 0/112 | 1/120 |
| Benign neoplasm of thyroid glandNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/122 | 0/124 | 0/112 | 1/120 |
| PneumoniaInfections and infestations | 1/122 | 0/124 | 0/112 | — |
| Event | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 31/122 | 34/124 | 33/112 | 31/120 |
| MalaiseGeneral disorders | 26/122 | 26/124 | 27/112 | 25/120 |
| Injection site painGeneral disorders | 14/122 | 29/124 | 10/112 | 12/120 |
| MyalgiaMusculoskeletal and connective tissue disorders | 28/122 | 25/124 | 22/112 | 20/120 |
| NasopharyngitisInfections and infestations | 4/122 | 6/124 | 6/112 | 8/120 |
| Upper respiratory tract infectionInfections and infestations | 4/122 | 1/124 | 2/112 | 8/120 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/122 | 3/124 | 3/112 | 7/120 |
| Age, Categorical(Participants) | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 72 | 75 | 62 | 76 | 285 |
| >=65 years | 50 | 49 | 51 | 44 | 194 |
| Age, Continuous(Years) | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 63.1 ± 9.39 | 62.9 ± 8.10 | 63.4 ± 9.01 | 62.2 ± 8.28 | 62.9 ± 8.69 |
| Sex: Female, Male(Participants) | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 76 | 65 | 63 | 64 | 268 |
| Male | 46 | 59 | 50 | 56 | 211 |
| Region of Enrollment(Participants) | ChimeriVax WN02 Vaccine Low Dose | ChimeriVax WN02 Vaccine Medium Dose | ChimeriVax WN02 Vaccine High Dose | Placebo | Total |
|---|---|---|---|---|---|
| United States | 122 | 124 | 113 | 120 | 479 |
The record gives a start of Oct 2008, a primary completion of Jun 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
West Nile Fever
Sanofi Pasteur, a Sanofi Company →